Edward J. Rapp - 09 May 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: Director
Issuer ticker: ABBV
Reported as of: 09 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2025, 17:05:04 UTC
Prior SEC filing: 30 Apr 2025
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, attorney-in-fact for Edward J. Rapp

Key filing fact

Edward J. Rapp filed Form 4 for AbbVie Inc. (ABBV) on 13 May 2025.

Key facts

This page summarizes Edward J. Rapp's Form 4 filing for AbbVie Inc. (ABBV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 May 2025, 17:05.

Change

Previous filing in this sequence was filed on 30 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001171780 Primary reporting owner

RAPP EDWARD J

Relationship: Director
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, attorney-in-fact for Edward J. Rapp
Signature date: 13 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +1,203
Change %: +3.6%
Price: $0.000000
Shares after: 34,458
Date: 09 May 2025
Ownership: Direct
Footnotes: F1, F2

ABBV holding

Common Stock, $0.01 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,388
Date: 09 May 2025
Ownership: By spouse in trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Footnote F2

Includes an additional 1,899 shares which, due to an administrative error, were inadvertently omitted from a previously filed form.

Footnote F3

The reporting person disclaims beneficial ownership of all securities held by his wife.